Clinical trial 2013

This study will be recruiting shortly, and is open to qualifying Type 1 Infants. Canadian location is Toronto Hospital for Sick Children. From Cure SMA-US: ISIS Pharmaceuticals Initiates Clinical Study in Infants with Spinal Muscular Atrophy. (April 23, 2013) Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study of ISIS-SMNRx in…

$140,000 Grant to Jocelyn Côté, PhD

Cure SMA Canada Awards $140,000 Grant to Joceyln Côté, PhD, University of Ottawa Cure SMA Canada has awarded a $140,000 research grant to Joceyln Côté, PhD, at The University of Ottawa, for his project, “Investigating the mechanism by which SMN regulates translation: identification of novel therapeutic targets.” Understanding the function of the SMN protein is…

First ever therapy for SMA

Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA…